Perioperative Pembrolizumab Betters Survival in Stage III/IV Head …
Oct 8, 2024 · Perioperative pembrolizumab (Keytruda) led to improved event-free survival (EFS) in patients with stage III or IVA, resected head and neck squamous cell carcinoma (HNSCC), meeting the primary end point of the phase 3 KEYNOTE-689 study (NCT03765918). 1 “These results are substantial, as KEYNOTE-689 marks the first positive trial in 2 decades for patients with resected, locally advanced head ...
September 2024 FDA Roundup: Key Decisions Drive Oncology …
Oct 2, 2024 · FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML. ICT01, a humanized anti-BTN3A monoclonal antibody, plus azacitidine and venetoclax (Venclexta) earned fast track designation for the treatment of acute myeloid leukemia in patients 75 or older or those who have comorbidities that preclude standard induction chemotherapy on …
GLP-1 Agonists Poised to Impact Breast Cancer Care
Sep 25, 2024 · Recent trends have brought GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), to front of mind when discussing general weight loss. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, multiple presentations focused on the weight loss aspect of GLP-1 agonists for patients with breast cancer.
Navtemadlin Monotherapy Shows Improvements in Hallmarks of …
Dec 8, 2024 · Navtemadlin (KRT-232), a novel p53 potentiating anticancer agent best-in-class MDM2 inhibitor, reduced biomarkers of disease severity in patients with relapsed or refractory (R/R) myelofibrosis (MF), suggesting the agent may …
First Patients Dosed in New Phase 3 Trials of Dato-DXd in NSCLC
Nov 4, 2024 · The first patients have been dosed in 3 phase 3 trials evaluating various combinations of datapotamab deruxtecan (Dato-DXd) for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC). 1 TROPION-Lung10 (NCT06357533) is investigating Dato-DXd plus rilvegostomig (AZD2936), a PD-1/TIGIT bispecific antibody, or rilvegostomig alone vs pembrolizumab (Keytruda) in ...
Positive Trials Continue to Shape the SCLC Treatment Landscape
Nov 8, 2024 · Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD.
IMforte Shows Benefits of Lurbinectedin/Atezolizumab in ES-SCLC
Oct 15, 2024 · Lurbinectedin (Zepzelca) plus the PD-L1 inhibitor atezolizumab (Tecentriq) led to positive topline results in the phase 3 IMforte study (NCT05091567) vs atezolizumab alone when used as maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC). 1 The combination showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) as assessed ...
FDA Grants Priority Review to Durvalumab in MIBC
Dec 6, 2024 · Behind the Phase 3 NIAGARA Trial. NIAGARA is a randomized, open-label, multicenter, global trial which enrolled adult patients with cisplatin-eligible MIBC with a clinical stage of T2-T4aN0/1M0. 2 Patients were evaluated, confirmed for radical cystectomy, and had urothelial carcinoma with or without divergent differentiation or histologic subtypes. . Further, patients were required to have an ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
Dec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Cilta-Cel Improves Overall Survival in Multiple Myeloma
Sep 30, 2024 · Treatment with the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of death by 45% vs standard of care (SOC) in patients with lenalidomide (Revlimid)-refractory multiple myeloma and at least 1 prior line of therapy, according to updated results from the phase 3 CARTITUDE-4 trial presented at the 2024 International Myeloma Society Annual Meeting. 1